Knockdown SiRNA Targeting GPR55 Reveals Significant Differences Between the Anti-inflammatory Actions of KLS-13019 and Cannabidiol

Overview

Journal Res Sq

Date 2024 Mar 11

PMID 38464007

Authors

Douglas E Brenneman

William A Kinney

Mark E McDonnell

Michael J Ippolito

Sara Jane Ward

Affiliations

Soon will be listed here.

Abstract

KLS-13019 was reported previously to reverse paclitaxel-induced mechanical allodynia in a mouse model of chemotherapy-induced peripheral neuropathy (CIPN). Recent studies demonstrated that paclitaxel-induced increases in inflammatory markers (GPR55, NLRP3 and IL-1b) of dorsal root ganglion (DRG) cultures were shown to be reversed by KLS-13019 treatment. The mechanism of action for KLS-13019-mediated reversal of paclitaxel-induced neuroinflammation now has been explored using GPR55 siRNA. Pretreatment of DRG cultures with GPR55 siRNA produced a 21% decrease of immunoreactive (IR) area for GPR55 in cell bodies and a 59% decrease in neuritic IR area, as determined by high content imaging. Using a 24-hour reversal treatment paradigm, paclitaxel-induced increases in the inflammatory markers were reversed back to control levels after KLS-3019 treatment. Decreases in these inflammatory markers produced by KLS-13019 were significantly attenuated by GPR55 siRNA co-treatment, with mean IR area responses being attenuated by 56% in neurites and 53% in cell bodies. These data indicate that the percentage decreases in siRNA-mediated attenuation of KLS-13019-related efficacy on the inflammatory markers were similar to the percentage knockdown observed for neuritic GPR55 IR area. Similar studies conducted with cannabidiol (CBD), the parent compound of KLS-13019, produced low efficacy (25%) reversal of all inflammatory markers that were poorly attenuated (29%) by GPR55 siRNA. CBD was shown previously to be ineffective in reversing paclitaxel-induced mechanical allodynia. The present studies indicated significant differences between the anti-inflammatory properties of KLS-13019 and CBD which may play a role in their observed differences in the reversibility of mechanical allodynia in a mouse model of CIPN.

References

Krames E . The role of the dorsal root ganglion in the development of neuropathic pain. Pain Med. 2014; 15(10):1669-85. DOI: 10.1111/pme.12413. View

Okine B, Mc Laughlin G, Gaspar J, Harhen B, Roche M, Finn D . Antinociceptive Effects of the GPR55 Antagonist CID16020046 Injected into the Rat Anterior Cingulate Cortex. Neuroscience. 2020; 443:19-29. DOI: 10.1016/j.neuroscience.2020.07.013. View

Brenneman D, Petkanas D, Kinney W . Pharmacological Comparisons Between Cannabidiol and KLS-13019. J Mol Neurosci. 2018; 66(1):121-134. PMC: 6150782. DOI: 10.1007/s12031-018-1154-7. View

Ward S, McAllister S, Kawamura R, Murase R, Neelakantan H, Walker E . Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol. 2013; 171(3):636-45. PMC: 3969077. DOI: 10.1111/bph.12439. View

Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson N, Leonova J . The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007; 152(7):1092-101. PMC: 2095107. DOI: 10.1038/sj.bjp.0707460. View

Scuteri A, Nicolini G, Miloso M, Bossi M, Cavaletti G, Windebank A . Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Res. 2006; 26(2A):1065-70. View

Brenneman D, Kinney W, Ward S . Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity. J Mol Neurosci. 2019; 68(4):603-619. PMC: 6615992. DOI: 10.1007/s12031-019-01321-z. View

Bonezzi C, Demartini L . Treatment options in postherpetic neuralgia. Acta Neurol Scand Suppl. 2000; 173:25-35; discussion 48-52. DOI: 10.1111/j.1600-0404.1999.tb07387.x. View

Nielsen S, Hasselsteen S, Dominiak H, Labudovic D, Reiter L, Dalton S . Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2022; 30(11):9441-9451. DOI: 10.1007/s00520-022-07312-y. View

10.

Shan L, Xu K, Ji L, Zeng Q, Liu Y, Wu Y . Injured sensory neurons-derived galectin-3 contributes to neuropathic pain via programming microglia in the spinal dorsal horn. Brain Behav Immun. 2024; 117:80-99. DOI: 10.1016/j.bbi.2024.01.002. View

11.

Staton P, Hatcher J, Walker D, Morrison A, Shapland E, Hughes J . The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain. 2008; 139(1):225-236. DOI: 10.1016/j.pain.2008.04.006. View

12.

Koyanagi M, Imai S, Matsumoto M, Iguma Y, Kawaguchi-Sakita N, Kotake T . Pronociceptive Roles of Schwann Cell-Derived Galectin-3 in Taxane-Induced Peripheral Neuropathy. Cancer Res. 2021; 81(8):2207-2219. DOI: 10.1158/0008-5472.CAN-20-2799. View

13.

Dedov V, Roufogalis B . Organisation of mitochondria in living sensory neurons. FEBS Lett. 1999; 456(1):171-4. DOI: 10.1016/s0014-5793(99)00951-5. View

14.

Kelley N, Jeltema D, Duan Y, He Y . The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019; 20(13). PMC: 6651423. DOI: 10.3390/ijms20133328. View

15.

Costa B, Trovato A, Comelli F, Giagnoni G, Colleoni M . The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2006; 556(1-3):75-83. DOI: 10.1016/j.ejphar.2006.11.006. View

16.

Argyriou A, Kyritsis A, Makatsoris T, Kalofonos H . Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res. 2014; 6:135-47. PMC: 3964029. DOI: 10.2147/CMAR.S44261. View

17.

Foss J, Farkas D, Huynh L, Kinney W, Brenneman D, Ward S . Behavioural and pharmacological effects of cannabidiol (CBD) and the cannabidiol analogue KLS-13019 in mouse models of pain and reinforcement. Br J Pharmacol. 2021; 178(15):3067-3078. DOI: 10.1111/bph.15486. View

18.

Guo L, Hamre 3rd J, Eldridge S, Behrsing H, Cutuli F, Mussio J . Editor's Highlight: Multiparametric Image Analysis of Rat Dorsal Root Ganglion Cultures to Evaluate Peripheral Neuropathy-Inducing Chemotherapeutics. Toxicol Sci. 2017; 156(1):275-288. PMC: 5837782. DOI: 10.1093/toxsci/kfw254. View

19.

Cherif H, Argaw A, Cecyre B, Bouchard A, Gagnon J, Javadi P . Role of GPR55 during Axon Growth and Target Innervation. eNeuro. 2016; 2(5). PMC: 4699829. DOI: 10.1523/ENEURO.0011-15.2015. View

20.

Brenneman D, Kinney W, McDonnell M, Zhao P, Abood M, Ward S . Anti-Inflammatory Properties of KLS-13019: a Novel GPR55 Antagonist for Dorsal Root Ganglion and Hippocampal Cultures. J Mol Neurosci. 2022; 72(9):1859-1874. PMC: 9398971. DOI: 10.1007/s12031-022-02038-2. View